In recent years,
there has been a growing interest in therapeutic
peptides within the pharmaceutical industry with more than 50 peptide
drugs on the market, approximately 170 in clinical trials, and >200
in preclinical development. However, the current state of the art
in peptide synthesis involves primarily legacy technologies with use
of large amounts of highly hazardous reagents and solvents and little
focus on green chemistry and engineering. In 2016, the ACS Green Chemistry
Institute Pharmaceutical Roundtable identified development of greener
processes for peptide API as a critical unmet need, and as a result,
a new Roundtable team formed to address this important area. The initial
focus of this new team is to highlight best practices in peptide synthesis
and encourage much needed innovations. In this Perspective, we aim
to summarize the current challenges of peptide synthesis and purification
in terms of sustainability, highlight possible solutions, and encourage
synergies between academia, the pharmaceutical industry, and contract
research organizations/contract manufacturing organizations.